-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Shi Bei
On November 2, Eli Lilly announced that it had reached an agreement with the US government, one of its loyal customers, and the US government agreed to purchase 614,000 doses of the company’s new crown neutralizing antibodies bamlanivimab and etesevimab for US$1.
29 billion
.
This combination therapy has been authorized by the FDA for emergency use for the treatment of mild to moderate COVID-19 or post-exposure prevention in high-risk individuals
Eli Lilly will provide at least 400,000 doses by the end of this year, and the rest will be completed by the end of January 2022
.
A year ago, this combination became the first antibody therapy approved for emergency use by the FDA for the treatment of COVID-19
.
But this spring, the FDA started to shelve the drug in some states due to its ineffectiveness against the gamma (gamma) first discovered in Brazil and the delta-plus mutant strain first discovered in India
In August of this year, the FDA resumed the authorization of Eli Lilly's neutralizing antibody, but only allowed to use it in states, territories and US jurisdictions where the prevalence of mutants resistant to double antibody therapy is low (less than 5%).
.
At that time, more than 20 states started using this therapy
Now, it's Lilly's turn to catch up with Regeneron's products
.
In the absence of competitors, Regeneron's new crown neutralizing antibodies are favored
Today, Eli Lilly has another competitor developing COVID-19 antibodies-GlaxoSmithKline and Vir
.
In May of this year, the FDA granted emergency use authorization for the two companies' new crown therapeutic antibody drug sotrovimab, but the two companies have not yet reached an agreement to provide the drug to the United States
